UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC. and PFIZER INC., Petitioner,

v.

SANOFI-AVENTIS DEUTSCHLAND GMBH, Patent Owner.

> Case No. IPR2018-01675 U.S. Patent No. 8,603,044 B2<sup>1</sup>

PATENT OWNER SANOFI-AVENTIS DEUTSCHLAND GMBH'S NOTICE OF APPEAL UNDER 37 C.F.R. § 90.2(a)

DOCKET

<sup>&</sup>lt;sup>1</sup> Pfizer Inc. was joined as a petitioner in this proceeding.

Pursuant to 35 U.S.C. §§ 141–144, 319 and 37 C.F.R. § 90.2(a), notice is hereby given that Patent Owner Sanofi-Aventis Deutschland GmbH ("Sanofi") appeals to the United States Court of Appeals for the Federal Circuit from the Final Written Decision (Paper No. 91) (the "Final Written Decision"), in IPR2018-01675, entered on May 29, 2020, by the United States Patent and Trademark Office, Patent Trial and Appeal Board (the "Board"), and from all orders, decisions, rulings, and opinions antecedent to the Final Written Decision. This appeal is timely under 35 U.S.C. § 142 and Rule 15(a)(1) of the Federal Rules of Appellate Procedure. A copy of the Final Written Decision is attached hereto as Exhibit A.

In accordance with 37 C.F.R. § 90.2(a)(3)(ii), Sanofi further indicates that the issues on appeal may include, but are not limited to, the Board's determination that claims 11, 14, 15, 18, and 19 of U.S. Patent Number 8,603,044 B2 have been shown to be unpatentable under 35 U.S.C. § 103 in view of the grounds of unpatentability identified in the Board's Final Written Decision, challenges to any findings supporting the determination, the Board's failure to properly consider evidence of record, the Board's legal and factual errors in undertaking the obviousness analysis, the Board's failure to consider Sanofi's arguments in support of patentability, the Board's procedural errors including its failure to strike and/or exclude certain of Petitioner's arguments and evidence and the Board's failure to provide Sanofi an opportunity to offer rebuttal argument and evidence, the Board's findings that conflict with the evidence of record and are not supported by substantial evidence, the Board's failure to provide Sanofi with sufficient due process, the Board's failure to provide Sanofi with just compensation, the constitutionality of the Administrative Patent Judges, and other issues decided adversely to Sanofi.

Simultaneous with this submission, a copy of this Notice of Appeal is being filed through the Patent Trial and Appeal Board End to End ("PTAB E2E") System. In addition, a copy of the Notice of Appeal, along with the required docketing fee, is being filed with the Clerk of Court for the United States Court of Appeals for the Federal Circuit. Dated: July 15, 2020

Respectfully submitted,

#### /Elizabeth Stotland Weiswasser/

**Elizabeth Stotland Weiswasser** Reg. No. 55,721 Anish R. Desai Reg. No. 73,760 Sudip K. Kundu Reg. No. 74,193 Anna Dwyer Admitted Pro Hac Vice Andrew Gesior Reg. No. 76,588 Kathryn M. Kantha Reg. No. 70,371 Weil, Gotshal & Manges LLP 767 Fifth Avenue New York, NY 10153 Phone: 212-310-8000 elizabeth.weiswasser@weil.com anish.desai@weil.com sudip.kundu@weil.com anna.dwyer@weil.com andrew.gesior@weil.com kathryn.kantha@weil.com

Adrian C. Percer Reg. No. 46,986 Weil, Gotshal & Manges LLP 201 Redwood Shores Parkway Redwood Shores, CA 94065 Phone: 650-802-3124 adrian.percer@weil.com

Robert T. Vlasis Admitted *Pro Hac Vice* William S. Ansley Reg. No. 67,828 Matthew D. Sieger Reg. No. 76,051

Weil, Gotshal & Manges LLP 2001 M Street NW, Ste. 600 Washington, D.C. 20036 Phone: 202-682-7000 sutton.ansley@weil.com matthew.sieger@weil.com

W. Karl Renner Reg No. 41,265 John S. Goetz Reg. No. 54,867 Joshua A. Griswold Reg. No. 46,310 Matthew S. Colvin Reg. No. 66,843 Kenneth W. Darby, Jr. Reg. No. 65,068 Fish & Richardson P.C. 3200 RBC Plaza 60 South Sixth Street Minneapolis, MN 55402 Phone: 202-783-5070 PTABInbound@fr.com

## DOCKET A L A R M



# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

### API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

#### LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

#### FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

#### E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.